Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Racial differences in mantle cell lymphoma in the United States

Authors: Yu Wang, Shuangge Ma

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

MCL (mantle cell lymphoma) is a rare subtype of NHL (non-Hodgkin lymphoma) with mostly poor prognosis. Different races have different etiology, presentation, and progression patterns.

Methods

Data were analyzed on MCL patients in the United States reported to the SEER (Surveillance, Epidemiology, and End Results) database between 1992 and 2009. SEER contains the most comprehensive population-based cancer information in the U.S., covering approximately 28% of the population. Racial groups analyzed included non-Hispanic whites, Hispanic whites, blacks, and Asians/PIs (Pacific Islanders). Patient characteristics, age-adjusted incidence rate, and survival rate were compared across races. Stratification by age, gender, and stage at diagnosis was considered. Multivariate analysis was conducted on survival.

Results

In the analysis of patients’ characteristics, distributions of gender, marital status, age at diagnosis, stage, and extranodal involvement were significantly different across races. For all three age groups and both male and female, non-Hispanic whites have the highest incidence rates. In the analysis of survival, for cancers diagnosed in the period of 1992–2004, no significant racial difference is observed. For cancers diagnosed in the period of 1999–2004, significant racial differences exist for the 40–64 age group and stage III and IV cancers.

Conclusions

Racial differences exist among MCL patients in the U.S. in terms of patients’ characteristics, incidence, and survival. More extended data collection and analysis are needed to more comprehensively describe and understand the racial differences.
Appendix
Available only for authorised users
Literature
2.
go back to reference Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peeters C, Gatter K, Grogan TM, Harris NL, Isaacson PG, Jaffe ES, Mason D, Pileri S, Ralfkiaer E, Stein H, Wanke RA: Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol. 1992, 16: 637-640. 10.1097/00000478-199207000-00001.CrossRefPubMed Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peeters C, Gatter K, Grogan TM, Harris NL, Isaacson PG, Jaffe ES, Mason D, Pileri S, Ralfkiaer E, Stein H, Wanke RA: Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol. 1992, 16: 637-640. 10.1097/00000478-199207000-00001.CrossRefPubMed
3.
go back to reference Hankin RC, Hunter SV: Mantle cell lymphoma. Arch Pathol Lab Med. 1999, 123 (12): 1182-1188.PubMed Hankin RC, Hunter SV: Mantle cell lymphoma. Arch Pathol Lab Med. 1999, 123 (12): 1182-1188.PubMed
4.
go back to reference Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, Kwak L, Yi Q, Du XL, Wang M: Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008, 113 (4): 791-798. 10.1002/cncr.23608.CrossRefPubMed Zhou Y, Wang H, Fang W, Romaguer JE, Zhang Y, Delasalle KB, Kwak L, Yi Q, Du XL, Wang M: Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008, 113 (4): 791-798. 10.1002/cncr.23608.CrossRefPubMed
5.
go back to reference Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA: SEER Cancer Statistics Review 1975–2009. 2012, Bethesda, MD: National Cancer Institute, Based on November 2010 SEER data submission Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA: SEER Cancer Statistics Review 1975–2009. 2012, Bethesda, MD: National Cancer Institute, Based on November 2010 SEER data submission
6.
go back to reference Jares P, Colomer D, Campo E: Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007, 7: 750-762. 10.1038/nrc2230.CrossRefPubMed Jares P, Colomer D, Campo E: Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007, 7: 750-762. 10.1038/nrc2230.CrossRefPubMed
7.
go back to reference Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, Repp R, Reiser M, Pott C, Pelz H, La Rosée P, Kirchner H, Kiewe P, Keller U, Buske C, Viardot A, Dreyling M: Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann Hematol. 2012, 91: 1765-1772. 10.1007/s00277-012-1534-y.CrossRefPubMed Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, Repp R, Reiser M, Pott C, Pelz H, La Rosée P, Kirchner H, Kiewe P, Keller U, Buske C, Viardot A, Dreyling M: Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann Hematol. 2012, 91: 1765-1772. 10.1007/s00277-012-1534-y.CrossRefPubMed
8.
go back to reference Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner R, Metzner B, Peter N, Wörmann B, Trümper L, Pfreundschuh M, Einsele H, Hiddemann W, Unterhalt M, Dreyling M: Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009, 27 (4): 511-518.CrossRefPubMed Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner R, Metzner B, Peter N, Wörmann B, Trümper L, Pfreundschuh M, Einsele H, Hiddemann W, Unterhalt M, Dreyling M: Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009, 27 (4): 511-518.CrossRefPubMed
9.
go back to reference Hoster E: Prognostic relevance of clinical risk factors in mantle cell lymphoma. Semin Hematol. 2011, 48 (3): 185-188. 10.1053/j.seminhematol.2011.06.001.CrossRefPubMed Hoster E: Prognostic relevance of clinical risk factors in mantle cell lymphoma. Semin Hematol. 2011, 48 (3): 185-188. 10.1053/j.seminhematol.2011.06.001.CrossRefPubMed
10.
go back to reference Chandran R, Gardiner SK, Simon M, Spurgeon SE: Survival trends in mantle cell lymphoma in the United States over 16 years 1992–2007. Leuk Lymphoma. 2012, 53 (8): 1488-1493. 10.3109/10428194.2012.656628.CrossRefPubMed Chandran R, Gardiner SK, Simon M, Spurgeon SE: Survival trends in mantle cell lymphoma in the United States over 16 years 1992–2007. Leuk Lymphoma. 2012, 53 (8): 1488-1493. 10.3109/10428194.2012.656628.CrossRefPubMed
11.
go back to reference Shenoy PJ, Malik N, Nooka A, Sinha R, Ward KC, Brawley OW, Lipscomb J, Flowers CR: Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2010, 117 (11): 2530-2540.CrossRefPubMed Shenoy PJ, Malik N, Nooka A, Sinha R, Ward KC, Brawley OW, Lipscomb J, Flowers CR: Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2010, 117 (11): 2530-2540.CrossRefPubMed
12.
go back to reference Griffiths R, Gleeson M, Knopf K, Danese M: Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). BMC Cancer. 2010, 10: 625-10.1186/1471-2407-10-625.CrossRefPubMedPubMedCentral Griffiths R, Gleeson M, Knopf K, Danese M: Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). BMC Cancer. 2010, 10: 625-10.1186/1471-2407-10-625.CrossRefPubMedPubMedCentral
13.
go back to reference Flowers CR, Shenoy PJ, Borate U, Bumpers K, Douglas-Holland T, King N, Brawley OW, Lipscomb J, Lechowicz MJ, Sinha R, Grover RS, Bernal-Mizrachi L, Kowalski J, Donnellan W, The A, Reddy V, Jaye DL, Foran J: Examining racial differences in diffuse large B-cell lymphoma presentation and survival. Leuk Lymphoma. 2013, 54: 268-276. 10.3109/10428194.2012.708751.CrossRefPubMedPubMedCentral Flowers CR, Shenoy PJ, Borate U, Bumpers K, Douglas-Holland T, King N, Brawley OW, Lipscomb J, Lechowicz MJ, Sinha R, Grover RS, Bernal-Mizrachi L, Kowalski J, Donnellan W, The A, Reddy V, Jaye DL, Foran J: Examining racial differences in diffuse large B-cell lymphoma presentation and survival. Leuk Lymphoma. 2013, 54: 268-276. 10.3109/10428194.2012.708751.CrossRefPubMedPubMedCentral
14.
go back to reference Evens AM, Antillón M, Aschebrook-Kilfoy B, Chiu BC: Racial disparities in Hodgkin’s lymphoma: a comprehensive population-based analysis. Ann Oncol. 2012, 23: 2128-2137. 10.1093/annonc/mdr578.CrossRefPubMed Evens AM, Antillón M, Aschebrook-Kilfoy B, Chiu BC: Racial disparities in Hodgkin’s lymphoma: a comprehensive population-based analysis. Ann Oncol. 2012, 23: 2128-2137. 10.1093/annonc/mdr578.CrossRefPubMed
15.
go back to reference Nabhan C, Byrtek M, Taylor MD, Friedberg JW, Cerhan JR, Hainsworth JD, Miller TP, Hirata J, Link BK, Flowers CR: Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the national LymphoCare study. Cancer. 2012, 118: 4842-4850. 10.1002/cncr.27513.CrossRefPubMed Nabhan C, Byrtek M, Taylor MD, Friedberg JW, Cerhan JR, Hainsworth JD, Miller TP, Hirata J, Link BK, Flowers CR: Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the national LymphoCare study. Cancer. 2012, 118: 4842-4850. 10.1002/cncr.27513.CrossRefPubMed
16.
go back to reference Kato I, Booza J, Quarshie WO, Schwartz K: Persistent socioeconomic inequalities in cancer survival in the United States: 1973–2007 surveillance, epidemiology and end results (SEER) data for breast cancer and non-Hodgkin’s lymphoma. J Registry Manag. 2012, 39: 158-166.PubMed Kato I, Booza J, Quarshie WO, Schwartz K: Persistent socioeconomic inequalities in cancer survival in the United States: 1973–2007 surveillance, epidemiology and end results (SEER) data for breast cancer and non-Hodgkin’s lymphoma. J Registry Manag. 2012, 39: 158-166.PubMed
17.
go back to reference Flowers CR, Fedewa SA, Chen AY, Nastoupil LJ, Lipscomb J, Brawley OW, Ward EM: Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev. 2012, 21: 1520-1530. 10.1158/1055-9965.EPI-12-0466.CrossRefPubMedPubMedCentral Flowers CR, Fedewa SA, Chen AY, Nastoupil LJ, Lipscomb J, Brawley OW, Ward EM: Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev. 2012, 21: 1520-1530. 10.1158/1055-9965.EPI-12-0466.CrossRefPubMedPubMedCentral
18.
go back to reference Shenoy PJ, Malik N, Sinha R, Nooka A, Nastoupil LJ, Smith M, Flowers CR: Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk. 2011, 11: 498-506. 10.1016/j.clml.2011.07.002.CrossRefPubMed Shenoy PJ, Malik N, Sinha R, Nooka A, Nastoupil LJ, Smith M, Flowers CR: Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk. 2011, 11: 498-506. 10.1016/j.clml.2011.07.002.CrossRefPubMed
19.
go back to reference Chim CS, Chan AC, Choo CK, Kwong YL, Lie AK, Liang R: Mantle cell lymphoma in the Chinese: clinicopathological features and treatment outcome. Am J Hematol. 1998, 59 (4): 295-301. 10.1002/(SICI)1096-8652(199812)59:4<295::AID-AJH5>3.0.CO;2-N.CrossRefPubMed Chim CS, Chan AC, Choo CK, Kwong YL, Lie AK, Liang R: Mantle cell lymphoma in the Chinese: clinicopathological features and treatment outcome. Am J Hematol. 1998, 59 (4): 295-301. 10.1002/(SICI)1096-8652(199812)59:4<295::AID-AJH5>3.0.CO;2-N.CrossRefPubMed
20.
go back to reference Griffiths R, Mikhael J, Gleeson M, Danese M, Dreyling M: Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood. 2011, 118: 4808-4816. 10.1182/blood-2011-04-348367.CrossRefPubMedPubMedCentral Griffiths R, Mikhael J, Gleeson M, Danese M, Dreyling M: Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood. 2011, 118: 4808-4816. 10.1182/blood-2011-04-348367.CrossRefPubMedPubMedCentral
21.
go back to reference Ederer F, Axtell LM, Cutler SJ: The relative survival rate: a statistical methodology. NCI Monogr. 1961, 6: 101-121. Ederer F, Axtell LM, Cutler SJ: The relative survival rate: a statistical methodology. NCI Monogr. 1961, 6: 101-121.
22.
go back to reference Wang Y, Ma S: Risk factors for etiology and prognosis of mantle cell lymphoma. Expert Rev Hematol. In press Wang Y, Ma S: Risk factors for etiology and prognosis of mantle cell lymphoma. Expert Rev Hematol. In press
23.
go back to reference Koshiol J, Lam TK, Gridley G, Check D, Brown LM, Landgren O: Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin’s lymphoma in veterans from the United States. J Clin Oncol. 2011, 29: 378-385. 10.1200/JCO.2010.30.1515.CrossRefPubMed Koshiol J, Lam TK, Gridley G, Check D, Brown LM, Landgren O: Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin’s lymphoma in veterans from the United States. J Clin Oncol. 2011, 29: 378-385. 10.1200/JCO.2010.30.1515.CrossRefPubMed
24.
go back to reference Smedby KE, Hjalgrim H: Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 2011, 21: 293-298. 10.1016/j.semcancer.2011.09.010.CrossRefPubMed Smedby KE, Hjalgrim H: Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 2011, 21: 293-298. 10.1016/j.semcancer.2011.09.010.CrossRefPubMed
25.
go back to reference Bulanda JR, Brown SL: Race-ethnic differences in marital quality and divorce. Soc Sci Res. 2007, 36: 945-967. 10.1016/j.ssresearch.2006.04.001.CrossRef Bulanda JR, Brown SL: Race-ethnic differences in marital quality and divorce. Soc Sci Res. 2007, 36: 945-967. 10.1016/j.ssresearch.2006.04.001.CrossRef
26.
go back to reference Aschebrook-Kilfoy B, Caces DB, Ollberding NJ, Smith SM, Chiu BC: An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA. Leuk Lymphoma. 2013, 54: 1677-1683. 10.3109/10428194.2012.760041.CrossRefPubMed Aschebrook-Kilfoy B, Caces DB, Ollberding NJ, Smith SM, Chiu BC: An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA. Leuk Lymphoma. 2013, 54: 1677-1683. 10.3109/10428194.2012.760041.CrossRefPubMed
27.
go back to reference Erber E, Maskarinec G, Lim U, Kolonel LN: Dietary vitamin D and risk of non-Hodgkin lymphoma: the multiethnic cohort. Br J Nutr. 2010, 103: 581-584. 10.1017/S0007114509992029.CrossRefPubMed Erber E, Maskarinec G, Lim U, Kolonel LN: Dietary vitamin D and risk of non-Hodgkin lymphoma: the multiethnic cohort. Br J Nutr. 2010, 103: 581-584. 10.1017/S0007114509992029.CrossRefPubMed
28.
go back to reference Erber E, Maskarinec G, Gill JK, Park SY, Kolonel LN: Dietary patterns and the risk of non-Hodgkin lymphoma: the multiethnic cohort. Leuk Lymphoma. 2009, 50: 1269-1275. 10.1080/10428190903030841.CrossRefPubMedPubMedCentral Erber E, Maskarinec G, Gill JK, Park SY, Kolonel LN: Dietary patterns and the risk of non-Hodgkin lymphoma: the multiethnic cohort. Leuk Lymphoma. 2009, 50: 1269-1275. 10.1080/10428190903030841.CrossRefPubMedPubMedCentral
29.
go back to reference Eriksson M, Hardell L, Carlberg M, Akerman M: Pesticide exposure as risk factor for non-Hodgkin lymphoma including histopathological subgroup analysis. Int J Cancer. 2008, 123: 1657-1663. 10.1002/ijc.23589.CrossRefPubMed Eriksson M, Hardell L, Carlberg M, Akerman M: Pesticide exposure as risk factor for non-Hodgkin lymphoma including histopathological subgroup analysis. Int J Cancer. 2008, 123: 1657-1663. 10.1002/ijc.23589.CrossRefPubMed
30.
go back to reference Cocco P, t’Mannetje A, Fadda D, Melis M, Becker N, de Sanjose S, Foretova L, Mareckova J, Staines A, Kleefeld S, Maynadié M, Nieters A, Brennan P, Boffetta P: Occupational exposure to solvents and risk of lymphoma subtypes: results from the Epilymph case–control study. Occup Environ Med. 2010, 67: 341-347. 10.1136/oem.2009.046839.CrossRefPubMed Cocco P, t’Mannetje A, Fadda D, Melis M, Becker N, de Sanjose S, Foretova L, Mareckova J, Staines A, Kleefeld S, Maynadié M, Nieters A, Brennan P, Boffetta P: Occupational exposure to solvents and risk of lymphoma subtypes: results from the Epilymph case–control study. Occup Environ Med. 2010, 67: 341-347. 10.1136/oem.2009.046839.CrossRefPubMed
31.
go back to reference Aminian O, Abedi A, Chavoshi F, Ghasemi M, Najarkolaei FR: Evaluation of occupational risk factors in non-Hodgkin lymphoma and Hodgkin’s disease in Iranian men. Iran J Cancer Prev. 2012, 4: 189-193. Aminian O, Abedi A, Chavoshi F, Ghasemi M, Najarkolaei FR: Evaluation of occupational risk factors in non-Hodgkin lymphoma and Hodgkin’s disease in Iranian men. Iran J Cancer Prev. 2012, 4: 189-193.
32.
go back to reference Skibola CF, Bracci PM, Nieters A, Brooks-Wilson A, de Sanjosé S, Hughes AM, Cerhan JR, Skibola DR, Purdue M, Kane E, Lan Q, Foretova L, Schenk M, Spinelli JJ, Slager SL, De Roos AJ, Smith MT, Roman E, Cozen W, Boffetta P, Kricker A, Zheng T, Lightfoot T, Cocco P, Benavente Y, Zhang Y, Hartge P, Linet MS, Becker N, Brennan P: Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol. 2010, 171: 267-276. 10.1093/aje/kwp383.CrossRefPubMedPubMedCentral Skibola CF, Bracci PM, Nieters A, Brooks-Wilson A, de Sanjosé S, Hughes AM, Cerhan JR, Skibola DR, Purdue M, Kane E, Lan Q, Foretova L, Schenk M, Spinelli JJ, Slager SL, De Roos AJ, Smith MT, Roman E, Cozen W, Boffetta P, Kricker A, Zheng T, Lightfoot T, Cocco P, Benavente Y, Zhang Y, Hartge P, Linet MS, Becker N, Brennan P: Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol. 2010, 171: 267-276. 10.1093/aje/kwp383.CrossRefPubMedPubMedCentral
33.
go back to reference Wong KF, Chan JK: Cytogenetic abnormalities in chronic B-cell lymphoproliferative disorders in Chinese patients. Cancer Genet Cytogenet. 1999, 111: 55-60. 10.1016/S0165-4608(98)00216-7.CrossRefPubMed Wong KF, Chan JK: Cytogenetic abnormalities in chronic B-cell lymphoproliferative disorders in Chinese patients. Cancer Genet Cytogenet. 1999, 111: 55-60. 10.1016/S0165-4608(98)00216-7.CrossRefPubMed
34.
go back to reference Pulte D, Redaniel MT, Brenner H, Jeffreys M: Changes in survival by ethnicity of patients with cancer between 1992–1996 and 2002–2006: is the discrepancy decreasing?. Ann Oncol. 2012, 23 (9): 2428-2434. 10.1093/annonc/mds023.CrossRefPubMed Pulte D, Redaniel MT, Brenner H, Jeffreys M: Changes in survival by ethnicity of patients with cancer between 1992–1996 and 2002–2006: is the discrepancy decreasing?. Ann Oncol. 2012, 23 (9): 2428-2434. 10.1093/annonc/mds023.CrossRefPubMed
35.
go back to reference Katzenberger T, Petzoldt C, Höller S, Mäder U, Kalla J, Adam P, Ott MM, Müller-Hermelink HK, Rosenwald A, Ott G: The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood. 2006, 107 (8): 3407-10.1182/blood-2005-10-4079.CrossRefPubMed Katzenberger T, Petzoldt C, Höller S, Mäder U, Kalla J, Adam P, Ott MM, Müller-Hermelink HK, Rosenwald A, Ott G: The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood. 2006, 107 (8): 3407-10.1182/blood-2005-10-4079.CrossRefPubMed
36.
go back to reference Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, Bikos V, Darzentas N, Papadaki T, Salaverria I, Pinyol M, Puig X, Palomero J, Vegliante MC, Amador V, Martinez-Trillos A, Stefancikova L, Wiestner A, Wilson W, Pott C, Calasanz MJ, Trim N, Erber W, Sander B, Ott G, Rosenwald A, Colomer D, Giné E, Siebert R, Lopez-Guillermo A: Status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012, 72 (20): 5307-5316. 10.1158/0008-5472.CAN-12-1615.CrossRefPubMedPubMedCentral Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, Bikos V, Darzentas N, Papadaki T, Salaverria I, Pinyol M, Puig X, Palomero J, Vegliante MC, Amador V, Martinez-Trillos A, Stefancikova L, Wiestner A, Wilson W, Pott C, Calasanz MJ, Trim N, Erber W, Sander B, Ott G, Rosenwald A, Colomer D, Giné E, Siebert R, Lopez-Guillermo A: Status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012, 72 (20): 5307-5316. 10.1158/0008-5472.CAN-12-1615.CrossRefPubMedPubMedCentral
37.
go back to reference Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003, 3: 185-197. 10.1016/S1535-6108(03)00028-X.CrossRefPubMed Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003, 3: 185-197. 10.1016/S1535-6108(03)00028-X.CrossRefPubMed
38.
go back to reference Clarke CA, Undurraga DM, Harasty PJ, Glaser SL, Morton LM, Holly EA: Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev. 2006, 15: 630-638. 10.1158/1055-9965.EPI-05-0549.CrossRefPubMed Clarke CA, Undurraga DM, Harasty PJ, Glaser SL, Morton LM, Holly EA: Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev. 2006, 15: 630-638. 10.1158/1055-9965.EPI-05-0549.CrossRefPubMed
39.
go back to reference Leux C, Maynadié M, Troussard X, Cabrera Q, Herry A, Le Guyader-Peyrou S, Le Gouill S, Monnereau A: Mantle cell lymphoma epidemiology: a population-based study in France. Ann Hematol. 2014, 93 (8): 1327-1333. 10.1007/s00277-014-2049-5.CrossRefPubMed Leux C, Maynadié M, Troussard X, Cabrera Q, Herry A, Le Guyader-Peyrou S, Le Gouill S, Monnereau A: Mantle cell lymphoma epidemiology: a population-based study in France. Ann Hematol. 2014, 93 (8): 1327-1333. 10.1007/s00277-014-2049-5.CrossRefPubMed
40.
go back to reference Naresh KN, Srinivas V, Soman CS: Distribution of various subtypes of non-Hodgkin’s lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO Classifications. Ann Oncol. 2000, 11 (Suppl 1): 63-67. 10.1093/annonc/11.suppl_1.S63.CrossRefPubMed Naresh KN, Srinivas V, Soman CS: Distribution of various subtypes of non-Hodgkin’s lymphoma in India: a study of 2773 lymphomas using R.E.A.L. and WHO Classifications. Ann Oncol. 2000, 11 (Suppl 1): 63-67. 10.1093/annonc/11.suppl_1.S63.CrossRefPubMed
41.
go back to reference Cheah CY, George A, Gine E, Giné E, Chiappella A, Kluin-Nelemans HC, Jurczak W, Krawczyk K, Mocikova H, Klener P, Salek D, Walewski J, Szymczyk M, Smolej L, Auer RL, Ritchie DS, Arcaini L, Williams ME, Dreyling M, Seymour JF, European Mantle Cell Lymphoma Network: Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol. 2013, 24 (8): 2119-2123. 10.1093/annonc/mdt139.CrossRefPubMed Cheah CY, George A, Gine E, Giné E, Chiappella A, Kluin-Nelemans HC, Jurczak W, Krawczyk K, Mocikova H, Klener P, Salek D, Walewski J, Szymczyk M, Smolej L, Auer RL, Ritchie DS, Arcaini L, Williams ME, Dreyling M, Seymour JF, European Mantle Cell Lymphoma Network: Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol. 2013, 24 (8): 2119-2123. 10.1093/annonc/mdt139.CrossRefPubMed
42.
go back to reference Greenland S: Multiple comparisons and association selection in general epidemiology. Int J Epidemiol. 2008, 37 (3): 430-434. 10.1093/ije/dyn064.CrossRefPubMed Greenland S: Multiple comparisons and association selection in general epidemiology. Int J Epidemiol. 2008, 37 (3): 430-434. 10.1093/ije/dyn064.CrossRefPubMed
Metadata
Title
Racial differences in mantle cell lymphoma in the United States
Authors
Yu Wang
Shuangge Ma
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-764

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine